Assessment of the Usefulness of Maternal Serum Beta-Human Chorionic Gonadotrophin as Predictive Marker for Pre-Eclampsia and Poor Clinical Neonatal Outcome in Sokoto, North-West Nigeria
Keywords:
βhCG, Maternal Preeclampsia, Serum, SokotoAbstract
Preeclampsia and its related maternal and neonatal complications remain a significant global public health threat and economic concern, especially in developing countries. It contributes to the high maternal and neonatal morbidity and mortality in Sokoto. Some of the analytes evaluated had low predictive power for preeclampsia and poor neonatal outcomes in Sokoto. The present study assessed the application of maternal serum beta human chorionic gonadotrophin (βhCG) levels as a predictive marker for preeclampsia and poor neonatal outcomes in Sokoto. This was a prospective case-control study conducted in some selected centres in the Sokoto metropolis. Two hundred participants (one hundred cases and one hundred controls) were recruited for this study. The data obtained were analysed using SPSS 25 version statistical software. The association between the variables was assessed using Pearson's linear correlation and unpaired student t test analysis, and predictive value for developing preeclampsia, and poor clinical neonatal outcome was determined using Receiver Operating Characteristic analysis. The results showed that maternal serum levels of βhCG of preeclamptic women were significantly higher compared to the controls (5189.91±7.35, 3943.71±53.21 mIU, p=0.000). There were significant negative correlations between βhCG, with birth weight (r=-0.371, p=0.000), and Apgar score (r= -0.385, p=0.000). The predictive power of βhCG for developing pre-eclampsia and poor neonatal outcomes was excellent and good, respectively. In conclusion, maternal serum βhCG levels at second trimesters and above may be useful in predicting preeclampsia and poor clinical neonatal outcomes.
References
1. Ramos-Vara JA. Immunohistochemistry: an overview. Vet Pathol. 2005;42(1):1–16. doi:10.1354/vp.42-1-1.
2. Dabbs DJ. Diagnostic Immunohistochemistry. 4th ed. Philadelphia, PA: Elsevier; 2014.
3. Prasad S, Gupta SC, Tyagi AK. Significance of immunohistochemistry in breast cancer. World J Cancer Res. 2015;2(1):1–10. PMCID: PMC4127609.
4. Weiss LM, Chu P. Immunohistochemical studies of metastatic carcinomas. In: Sternberg SS, Antonioli DA, Carter D, Mills SE, Oberman HA, editors. Diagnostic Surgical Pathology. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2004. p. 45–66.
5. Wolff AC, Hammond MEH, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997–4013. doi:10.1200/JCO.2013.50.9984.
6. Dowsett M, Nielsen TO, A’Hern R, Bartlett J, Coombes RC, Cuzick J, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst. 2011;103(22):1656–64. doi:10.1093/jnci/djr393
7. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signalling axis. J Clin Oncol. 2005;23(33):8286–91. doi:10.1200/JCO.2005.03.121
8. Chetty R, Govender D. Immunohistochemistry in diagnostic pathology of infectious diseases. Arch Pathol Lab Med. 2020;144(7):851–60. doi:10.5858/arpa.2019-0394-RA
9. Bray F, Laversanne M, Weiderpass E, Soerjomataram I. The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer. 2021;127(16):3029–30.
10. Jedy-Agba E, Oga E, Odutola M, Abdullahi YM, Popoola A, Balogun O, et al. Cancer incidence in Nigeria: A report from population-based cancer registries. Cancer Epidemiol. 2020; 67:101795.
11. Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, et al. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021 Apr 5. doi: 10.1002/ijc.33588. Epub ahead of print. PMID: 33818764.
12. Alatise OI, Schrauzer T, Adepoju A, Lawal OO, Okunade KS, Nwankwo KC, et al. Cancer care in Nigeria: Need for a comprehensive approach. Lancet Oncol. 2020;21(8): e342–50.
13. Carter JM, Ehinger M, Greipp PT, Vrana JA, Halling KC, Jenkins SM, et al. Immunohistochemistry in diagnostic pathology: advances and clinical applications. Arch Pathol Lab Med. 2021;145(4):452–62.
14. Tavassoli FA, Devilee P, editors. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon: IARC Press; 2003.
15. World Health Organisation. Guide to Cancer Early Diagnosis. Geneva: WHO; 2020.
16. Patel K, Strother R M, Ndiangui F, Chumba D, Jacobson W, Dodson C, et al (2016). Development of immunohistochemistry services for cancer care in western Kenya: Implications for low- and middle-income countries. Afr J of Lab Med. 2016;5(1), 187. https://doi.org/10.4102/ajlm.v5i1.187
17. Batta H, Dogo D, Ekanem VJ, Saidu Y, Musa AB, Okeke EN, et al. Diagnostic utility and limitations of immunohistochemistry in Nigeria. Niger J Clin Pract. 2022;25(3):345–52.
18. Thomas JO. Histopathology in Nigeria: The challenges. Niger Med J. 2020;61(3):118–22.
19. Orakwe JC, Okonkwo CA, Nwaogu IC, Udeh CM, Onwukeme K, Agboeze J, et al. Status and patterns of immunohistochemistry in Nigerian tertiary hospitals: A cross-sectional analysis. Afr J Lab Med. 2023;12(1):a1598.
20. Akinwale OO, Nwankwo KC, Adesina A, Ogun GO, Adebamowo CA, Salako O, et al. Immunohistochemistry and cancer diagnostics in West Africa: A multicentre review. West Afr J Med. 2021;38(4):320–6.
21. Babalola EO, Ojo OS, Ibrahim M, Aina OO, Olowu AO, Afolabi AO, et al. Breast cancer molecular subtyping using IHC in Ibadan, Nigeria. Afr Health Sci. 2021;21(1):103–10.
22. Muwonge R, Swaminathan R, Sankaranarayanan R. Cancer control in developing countries: Implementation of the WHO guidelines. Int J Cancer. 2018;143(6):1333–9.
23. Ghartey FN, Agyeman-Yeboah J, Tetteh DA, Boamah I, Owusu-Afriyie O, Oppong J, et al. Histopathologic patterns of cancers in Ghana: A 5-year retrospective review. Ghana Med J. 2020;54(2):79–85.
24. Fall PA, Cissé ML, Seck B, Diagne M, Toure A, Diallo A, et al. Diagnostic delay in cancer care in Senegal: Role of pathology services. Pan Afr Med J. 2021; 39:203.
25. Federal Ministry of Health (Nigeria). National Cancer Control Plan (2018–2022). Abuja: FMOH; 2022.
26. Ghana Ministry of Health. National Strategy for Cancer Control in Ghana (2020–2024). Accra: MOH; 2020.
27. Faduyile FA, Soyemi SS, Akinola OI, Idowu AO, Obafemi OT, Odukoya O, et al. Human resource gaps in Nigerian pathology laboratories. Ann Trop Pathol. 2020;11(2):61–6.
28. Nwogu CM, Anyanwu S, Irekpita E, Okonkwo UC, Chidebe RC, Oduyebo O, et al. Fixation and processing challenges in IHC: An experience from Nigeria. Niger J Surg Sci. 2020;10(2):61–4.
29. Tshimwanga TM, Ngoyi JB, Ngoma T, Lubinga SJ, Mbuyi-Muamba JM, et al. The role of IHC in breast cancer diagnostics in East and Southern Africa. Afr J Med Med Sci. 2021;50(3):291–6.
30. Adewoyin AS, Olowoselu FO. The promise and perils of IHC in Nigeria’s oncology ecosystem. Afr J Lab Med. 2023;12(1):a1573.
31. Wright AJ, Thomas JD. Regional disparities in immunodiagnostics in Africa. J Glob Oncol. 2020;6(3):520–9.
32. Pathologists Overseas. Supporting African labs in IHC development: Impact report 2021. [Internet]. 2021 [cited 2025 Jul 14]. Available from: https://www.pathologistsoverseas.org Accessed Date 16 July 2025?
33. World Health Organisation, Regional Office for Africa. National Cancer Control Plans: Status in the WHO African Region. Brazzaville: WHO AFRO; 2 021. ? URL, Accessed Date 14th July 2025
34. African Cancer Registry Network (AFCRN). IHC utilisation and data harmonisation in member registries. AFCRN Bull. 2022;10(1):3–8.
35. Roche Diagnostics. Africa IHC Access Initiative: 2023 Report. [Internet]. 2023 [cited 2025 Jul 14]. Available from: https://www.roche.com/africa-ihc. Access Date 2025 July 14
36. Vigdorovits, A., Köteles, M. M., Olteanu, G., & Pop, O. (2022). Breaking Barriers: AI’s Influence on Pathology and Oncology in Resource-Scarce Medical Systems. Cancers, 15(23), 5692. https://doi.org/10.3390/cancers15235692
37. Ekenze SO, Okoro CI, Agwu NP, Okpara OC, Nwagboso EC, Onuoka CI, et al. Delays to cancer care and outcomes in a low-resource setting: The experience from Enugu, South-East Nigeria. J Cancer Epidemiol. 2022; 2022:9809059. doi:10.1155/2022/9809059.•
38. WHO Regional Office for Africa. National Cancer Control Plans: Status in the WHO African Region. Brazzaville: WHO AFRO; 2021.
Available from: https://www.afro.who.int
39. Pathologists Overseas. Supporting African labs in IHC development: Impact report 2021. [Internet]. ?URL, Accessed Date 27 August 2025
Available from: https://www.pathologistsoverseas.org
40. Salako O, Ojeniran MA, Fatiregun OA, Ali-Gombe A, Alabi O, Ayandipo O, et al. Access to oncology services in Nigeria: The diagnostic bottleneck. BMC Health Serv Res. 2020;20(1):65. https://doi.org/10.1186/s12913-020-4892-4
